TickerFacts.

Repligen Corp (RGEN): Gross Profit

Revenue minus cost of revenue for the same annual period and currency, computed by TickerFacts from the filed figures. The issuer may report gross profit or margin on a different basis.

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

$386.25M
Year ended 2025-12-31
-5.4%
3-year compound annual growth
+13.0%
5-year compound annual growth
+23.1%
10-year compound annual growth
$455.71M2010-03-31: $16.81M2011-03-31: $21.71M2012-12-31: $37.31M2013-12-31: $45.69M2014-12-31: $35.53M2015-12-31: $48.29M2016-12-31: $57.42M2017-12-31: $74.19M2018-12-31: $107.50M2019-12-31: $151.15M2020-12-31: $209.63M2021-12-31: $391.25M2022-12-31: $455.71M2023-12-31: $278.44M2024-12-31: $274.64M2025-12-31: $386.25M$386.25M
2010-03-31 Gross Profit (USD) 2025-12-31
Period endedGross ProfitChange YoYSource filing
2025-12-31$386.25M+40.6%2026-02-26, From 2025-01-01
2024-12-31$274.64M-1.4%2026-02-26, From 2024-01-01
2023-12-31$278.44M-38.9%2026-02-26, From 2023-01-01
2022-12-31$455.71M+16.5%2025-03-14, From 2022-01-01
2021-12-31$391.25M+86.6%2024-11-18, From 2021-01-01
2020-12-31$209.63M+38.7%2023-02-22, From 2020-01-01
2019-12-31$151.15M+40.6%2022-02-17, From 2019-01-01
2018-12-31$107.50M+44.9%2021-02-24, From 2018-01-01
2017-12-31$74.19M+29.2%2020-02-26, From 2017-01-01
2016-12-31$57.42M+18.9%2019-03-01, From 2016-01-01
2015-12-31$48.29M+35.9%2018-02-22, From 2015-01-01
2014-12-31$35.53M-22.2%2017-02-23, From 2014-01-01
2013-12-31$45.69M+22.5%2016-02-25, From 2013-01-01
2012-12-31$37.31Mn/a2015-03-17, From 2012-01-01
No annual figure between 2011-03-31 and 2012-12-31.
2011-03-31$21.71M+29.1%2013-03-15, From 2010-04-01
2010-03-31$16.81Mn/a2012-03-15, From 2009-04-01

Gross Profit at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedGross ProfitChange YoY
Repligen Corp (RGEN)2025-12-31$386.25M+40.6%
ADMA Biologics, Inc. (ADMA)2025-12-31$292.76M+33.3%
Novavax Inc (NVAX)2025-12-31$1.05B+119.1%
Bio-Techne Corp (TECH)2026-06-30$799.07M+1.1%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$1.17B+36.4%
Twist Bioscience Corp (TWST)2025-09-30$191.00M+43.2%
Moderna, Inc. (MRNA)2025-12-31$1.08B-39.3%
Adaptive Biotechnologies Corp (ADPT)2025-12-31$205.62M+92.4%
Vericel Corp (VCEL)2025-12-31$205.60M+19.5%

Compare RGEN, ADMA, NVAX, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗